EMA announces collaboration with Israel, and USP updates chapter on elemental impurities.
Advertisement
ISPE has updated its ISPE GAMP guidance on testing of GXP systems to help companies efficiently test computerized and software-based systems.
France has asked the European Medicines Agency (EMA) to review third- and fourth-generation combined oral contraceptives to determine if these drugs should be restricted to women who cannot take other combined oral contraceptives. The agency’s Pharmacovigilance Risk Assessment Committee will review the drugs and give its opinion and determine if a EU-wide recommendation is necessary.
EMA has published guidance on preparing and reviewing product characteristic summaries. The guidance outlines the European Commission’s principles on product characteristic summaries.
EMA announced an agreement for collaboration with Israel on industrial standards. The agreement includes “the mutual recognition of the conclusions of GMP inspections, of manufacturing and import authorizations, and of certification of conformity of each batch without rechecking at import.”
The United States Pharmacopeial Convention (USP) has posted a revision bulletin on <232> Elemental Impurities—Limits and <233> Elemental Impurities—Procedures.
FDA has announced its Vaccines and Related Biological Products Advisory Committee Meeting will be held on Feb. 27, 2013. FDA is accepting public participation in the way of written submissions to be made on or before Feb. 20 and oral presentations that can be scheduled for Feb. 27, 2013.
Despite best efforts to ensure a contract organization is following GMPs, a warning letter is issued by the FDA. Susan J. Schniepp, distinguished fellow at Nelson Labs, and Siegfried Schmitt, PhD, vice president, Technical at Parexel, provide advice for create a robust supplier selection and oversight system.
Nate Edwards of Arya Consulting, Elisabeth Gardiner of Tevard Biosciences, and Donny Xu of the RTW Institute discuss global competition for rare disease therapies.
The FDA grants accelerated approval to neladalkib for pretreated ALK-positive lung cancer, showing how next-gen kinase inhibitors tackle drug resistance
The FDA approves oral SERD giredestrant for ESR1-mutated breast cancer after a 62% risk cut, tying supply to testing ahead of a November 30, 2026 adjuvant decision.